nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—kidney cancer—bone cancer	0.411	1	CtDrD
Sunitinib—CHEK2—bone cancer	0.186	0.598	CbGaD
Sunitinib—KIT—bone cancer	0.0981	0.315	CbGaD
Sunitinib—CYP3A4—bone cancer	0.0272	0.0873	CbGaD
Sunitinib—ABCC2—Carboplatin—bone cancer	0.00896	0.136	CbGbCtD
Sunitinib—ABCC4—Methotrexate—bone cancer	0.00836	0.127	CbGbCtD
Sunitinib—ABCG2—Carboplatin—bone cancer	0.0081	0.123	CbGbCtD
Sunitinib—ABCC2—Cisplatin—bone cancer	0.00766	0.116	CbGbCtD
Sunitinib—ABCG2—Cisplatin—bone cancer	0.00692	0.105	CbGbCtD
Sunitinib—ABCC2—Doxorubicin—bone cancer	0.00513	0.0777	CbGbCtD
Sunitinib—ABCC2—Methotrexate—bone cancer	0.00497	0.0753	CbGbCtD
Sunitinib—ABCG2—Doxorubicin—bone cancer	0.00464	0.0703	CbGbCtD
Sunitinib—ABCG2—Methotrexate—bone cancer	0.00449	0.0681	CbGbCtD
Sunitinib—ABCB1—Cisplatin—bone cancer	0.0025	0.0378	CbGbCtD
Sunitinib—ABCB1—Doxorubicin—bone cancer	0.00167	0.0253	CbGbCtD
Sunitinib—ABCB1—Methotrexate—bone cancer	0.00162	0.0245	CbGbCtD
Sunitinib—CYP3A4—Doxorubicin—bone cancer	0.001	0.0152	CbGbCtD
Sunitinib—PRKAA2—tendon—bone cancer	0.000284	0.00609	CbGeAlD
Sunitinib—PKN1—connective tissue—bone cancer	0.00028	0.006	CbGeAlD
Sunitinib—STK17B—tendon—bone cancer	0.000274	0.00586	CbGeAlD
Sunitinib—STK17B—bone marrow—bone cancer	0.000265	0.00568	CbGeAlD
Sunitinib—CSNK2A1—connective tissue—bone cancer	0.000265	0.00567	CbGeAlD
Sunitinib—MYLK—connective tissue—bone cancer	0.000262	0.0056	CbGeAlD
Sunitinib—STK4—connective tissue—bone cancer	0.000257	0.00549	CbGeAlD
Sunitinib—STK17A—tendon—bone cancer	0.000252	0.0054	CbGeAlD
Sunitinib—CDK14—tendon—bone cancer	0.000249	0.00532	CbGeAlD
Sunitinib—LATS2—tendon—bone cancer	0.000245	0.00525	CbGeAlD
Sunitinib—STK17A—bone marrow—bone cancer	0.000244	0.00523	CbGeAlD
Sunitinib—HIPK2—connective tissue—bone cancer	0.000243	0.00519	CbGeAlD
Sunitinib—TYRO3—connective tissue—bone cancer	0.000243	0.00519	CbGeAlD
Sunitinib—HIPK3—connective tissue—bone cancer	0.000243	0.00519	CbGeAlD
Sunitinib—ALK—connective tissue—bone cancer	0.000243	0.00519	CbGeAlD
Sunitinib—CDK14—spinal cord—bone cancer	0.00024	0.00513	CbGeAlD
Sunitinib—PAK3—spinal cord—bone cancer	0.000236	0.00506	CbGeAlD
Sunitinib—RPS6KA5—bone marrow—bone cancer	0.000234	0.00501	CbGeAlD
Sunitinib—CLK4—tendon—bone cancer	0.000233	0.00498	CbGeAlD
Sunitinib—SBK1—tendon—bone cancer	0.00023	0.00492	CbGeAlD
Sunitinib—CLK4—bone marrow—bone cancer	0.000226	0.00483	CbGeAlD
Sunitinib—DAPK1—tendon—bone cancer	0.000225	0.00481	CbGeAlD
Sunitinib—PHKG1—tendon—bone cancer	0.000225	0.00481	CbGeAlD
Sunitinib—ROCK1—connective tissue—bone cancer	0.000224	0.00479	CbGeAlD
Sunitinib—ITK—bone marrow—bone cancer	0.000223	0.00477	CbGeAlD
Sunitinib—SBK1—spinal cord—bone cancer	0.000222	0.00475	CbGeAlD
Sunitinib—PHKG1—spinal cord—bone cancer	0.000217	0.00464	CbGeAlD
Sunitinib—RPS6KA1—tendon—bone cancer	0.000216	0.00461	CbGeAlD
Sunitinib—RIOK1—tendon—bone cancer	0.000216	0.00461	CbGeAlD
Sunitinib—MARK2—tendon—bone cancer	0.000211	0.00452	CbGeAlD
Sunitinib—TNIK—tendon—bone cancer	0.000211	0.00452	CbGeAlD
Sunitinib—BRD4—bone marrow—bone cancer	0.000211	0.00451	CbGeAlD
Sunitinib—STK11—bone marrow—bone cancer	0.000211	0.00451	CbGeAlD
Sunitinib—SGK3—tendon—bone cancer	0.000209	0.00448	CbGeAlD
Sunitinib—MAP4K4—connective tissue—bone cancer	0.000209	0.00448	CbGeAlD
Sunitinib—RIOK1—bone marrow—bone cancer	0.000209	0.00447	CbGeAlD
Sunitinib—RPS6KA1—bone marrow—bone cancer	0.000209	0.00447	CbGeAlD
Sunitinib—RPS6KA1—spinal cord—bone cancer	0.000208	0.00445	CbGeAlD
Sunitinib—RIOK1—spinal cord—bone cancer	0.000208	0.00445	CbGeAlD
Sunitinib—ICK—tendon—bone cancer	0.000208	0.00444	CbGeAlD
Sunitinib—FLT3—connective tissue—bone cancer	0.000206	0.00441	CbGeAlD
Sunitinib—TNIK—spinal cord—bone cancer	0.000204	0.00436	CbGeAlD
Sunitinib—RPS6KA3—connective tissue—bone cancer	0.000203	0.00435	CbGeAlD
Sunitinib—SGK3—bone marrow—bone cancer	0.000203	0.00434	CbGeAlD
Sunitinib—MAP2K1—connective tissue—bone cancer	0.000202	0.00432	CbGeAlD
Sunitinib—SGK3—spinal cord—bone cancer	0.000202	0.00432	CbGeAlD
Sunitinib—ICK—bone marrow—bone cancer	0.000201	0.0043	CbGeAlD
Sunitinib—CHEK2—tendon—bone cancer	0.0002	0.00429	CbGeAlD
Sunitinib—NUAK1—tendon—bone cancer	0.0002	0.00429	CbGeAlD
Sunitinib—ICK—spinal cord—bone cancer	0.0002	0.00428	CbGeAlD
Sunitinib—OXSR1—tendon—bone cancer	0.000199	0.00425	CbGeAlD
Sunitinib—INSR—tendon—bone cancer	0.000199	0.00425	CbGeAlD
Sunitinib—SNRK—tendon—bone cancer	0.000199	0.00425	CbGeAlD
Sunitinib—CLK1—connective tissue—bone cancer	0.000198	0.00424	CbGeAlD
Sunitinib—RPS6KA2—tendon—bone cancer	0.000196	0.00419	CbGeAlD
Sunitinib—STK38—tendon—bone cancer	0.000196	0.00419	CbGeAlD
Sunitinib—BMP2K—connective tissue—bone cancer	0.000195	0.00416	CbGeAlD
Sunitinib—CHEK2—bone marrow—bone cancer	0.000194	0.00415	CbGeAlD
Sunitinib—AURKC—tendon—bone cancer	0.000194	0.00415	CbGeAlD
Sunitinib—NUAK1—spinal cord—bone cancer	0.000193	0.00414	CbGeAlD
Sunitinib—PKN1—tendon—bone cancer	0.000193	0.00412	CbGeAlD
Sunitinib—CSNK1G2—tendon—bone cancer	0.000193	0.00412	CbGeAlD
Sunitinib—OXSR1—bone marrow—bone cancer	0.000193	0.00412	CbGeAlD
Sunitinib—SNRK—bone marrow—bone cancer	0.000193	0.00412	CbGeAlD
Sunitinib—INSR—spinal cord—bone cancer	0.000192	0.0041	CbGeAlD
Sunitinib—OXSR1—spinal cord—bone cancer	0.000192	0.0041	CbGeAlD
Sunitinib—SNRK—spinal cord—bone cancer	0.000192	0.0041	CbGeAlD
Sunitinib—PRKAA1—connective tissue—bone cancer	0.00019	0.00407	CbGeAlD
Sunitinib—PRPF4—tendon—bone cancer	0.00019	0.00406	CbGeAlD
Sunitinib—RPS6KA2—bone marrow—bone cancer	0.000189	0.00405	CbGeAlD
Sunitinib—STK38—bone marrow—bone cancer	0.000189	0.00405	CbGeAlD
Sunitinib—RPS6KA2—spinal cord—bone cancer	0.000189	0.00404	CbGeAlD
Sunitinib—PTK2B—connective tissue—bone cancer	0.000188	0.00402	CbGeAlD
Sunitinib—PRPF4B—tendon—bone cancer	0.000187	0.004	CbGeAlD
Sunitinib—PKN1—bone marrow—bone cancer	0.000187	0.00399	CbGeAlD
Sunitinib—CSNK1G2—bone marrow—bone cancer	0.000187	0.00399	CbGeAlD
Sunitinib—CSNK1G2—spinal cord—bone cancer	0.000186	0.00398	CbGeAlD
Sunitinib—PKN1—spinal cord—bone cancer	0.000186	0.00398	CbGeAlD
Sunitinib—STK39—tendon—bone cancer	0.000185	0.00395	CbGeAlD
Sunitinib—PRPF4—bone marrow—bone cancer	0.000184	0.00393	CbGeAlD
Sunitinib—PRPF4—spinal cord—bone cancer	0.000183	0.00392	CbGeAlD
Sunitinib—CSNK2A1—tendon—bone cancer	0.000182	0.0039	CbGeAlD
Sunitinib—PRPF4B—bone marrow—bone cancer	0.000181	0.00388	CbGeAlD
Sunitinib—PRPF4B—spinal cord—bone cancer	0.00018	0.00386	CbGeAlD
Sunitinib—STK39—bone marrow—bone cancer	0.000179	0.00383	CbGeAlD
Sunitinib—STK39—spinal cord—bone cancer	0.000178	0.00381	CbGeAlD
Sunitinib—MAP3K2—connective tissue—bone cancer	0.000177	0.00378	CbGeAlD
Sunitinib—CSNK2A1—bone marrow—bone cancer	0.000176	0.00377	CbGeAlD
Sunitinib—CSNK2A1—spinal cord—bone cancer	0.000176	0.00376	CbGeAlD
Sunitinib—MYLK—spinal cord—bone cancer	0.000173	0.00371	CbGeAlD
Sunitinib—PHKG2—tendon—bone cancer	0.000173	0.00371	CbGeAlD
Sunitinib—STK24—tendon—bone cancer	0.000172	0.00369	CbGeAlD
Sunitinib—PLK4—bone marrow—bone cancer	0.000172	0.00368	CbGeAlD
Sunitinib—TYK2—connective tissue—bone cancer	0.000172	0.00368	CbGeAlD
Sunitinib—DAPK2—tendon—bone cancer	0.00017	0.00365	CbGeAlD
Sunitinib—STK16—tendon—bone cancer	0.000168	0.00359	CbGeAlD
Sunitinib—STK24—bone marrow—bone cancer	0.000167	0.00357	CbGeAlD
Sunitinib—HIPK2—tendon—bone cancer	0.000167	0.00357	CbGeAlD
Sunitinib—HIPK3—tendon—bone cancer	0.000167	0.00357	CbGeAlD
Sunitinib—RPS6KB1—connective tissue—bone cancer	0.000166	0.00356	CbGeAlD
Sunitinib—RET—connective tissue—bone cancer	0.000165	0.00354	CbGeAlD
Sunitinib—DAPK2—bone marrow—bone cancer	0.000165	0.00353	CbGeAlD
Sunitinib—TNK1—tendon—bone cancer	0.000165	0.00353	CbGeAlD
Sunitinib—RIOK2—tendon—bone cancer	0.000165	0.00353	CbGeAlD
Sunitinib—AXL—connective tissue—bone cancer	0.000165	0.00353	CbGeAlD
Sunitinib—DAPK2—spinal cord—bone cancer	0.000164	0.00352	CbGeAlD
Sunitinib—MAP4K1—tendon—bone cancer	0.000163	0.0035	CbGeAlD
Sunitinib—HIPK3—bone marrow—bone cancer	0.000162	0.00346	CbGeAlD
Sunitinib—HIPK2—spinal cord—bone cancer	0.000161	0.00344	CbGeAlD
Sunitinib—TYRO3—spinal cord—bone cancer	0.000161	0.00344	CbGeAlD
Sunitinib—DAPK3—tendon—bone cancer	0.00016	0.00343	CbGeAlD
Sunitinib—RIOK2—bone marrow—bone cancer	0.00016	0.00342	CbGeAlD
Sunitinib—RIOK2—spinal cord—bone cancer	0.000159	0.00341	CbGeAlD
Sunitinib—CLK2—tendon—bone cancer	0.000159	0.0034	CbGeAlD
Sunitinib—MAP4K1—bone marrow—bone cancer	0.000158	0.00339	CbGeAlD
Sunitinib—MAP4K2—tendon—bone cancer	0.000158	0.00338	CbGeAlD
Sunitinib—FGFR2—connective tissue—bone cancer	0.000157	0.00336	CbGeAlD
Sunitinib—JAK2—connective tissue—bone cancer	0.000156	0.00335	CbGeAlD
Sunitinib—STK3—tendon—bone cancer	0.000156	0.00334	CbGeAlD
Sunitinib—DAPK3—spinal cord—bone cancer	0.000155	0.00331	CbGeAlD
Sunitinib—FYN—connective tissue—bone cancer	0.000154	0.0033	CbGeAlD
Sunitinib—DYRK1A—Idarubicin—Epirubicin—bone cancer	0.000154	0.0776	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Epirubicin—bone cancer	0.000154	0.0776	CbGdCrCtD
Sunitinib—DYRK1A—Doxorubicin—Epirubicin—bone cancer	0.000154	0.0776	CbGdCrCtD
Sunitinib—CLK2—bone marrow—bone cancer	0.000154	0.00329	CbGeAlD
Sunitinib—MAP4K2—bone marrow—bone cancer	0.000153	0.00327	CbGeAlD
Sunitinib—MERTK—tendon—bone cancer	0.000147	0.00314	CbGeAlD
Sunitinib—FLT1—connective tissue—bone cancer	0.000146	0.00312	CbGeAlD
Sunitinib—MAP4K4—tendon—bone cancer	0.000144	0.00308	CbGeAlD
Sunitinib—DYRK1A—Epirubicin—Doxorubicin—bone cancer	0.000143	0.0718	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Doxorubicin—bone cancer	0.000143	0.0718	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Doxorubicin—bone cancer	0.000143	0.0718	CbGdCrCtD
Sunitinib—MERTK—bone marrow—bone cancer	0.000142	0.00304	CbGeAlD
Sunitinib—MAP3K12—tendon—bone cancer	0.000142	0.00303	CbGeAlD
Sunitinib—RPS6KA3—tendon—bone cancer	0.00014	0.00299	CbGeAlD
Sunitinib—MAP4K4—bone marrow—bone cancer	0.000139	0.00298	CbGeAlD
Sunitinib—YES1—connective tissue—bone cancer	0.000139	0.00298	CbGeAlD
Sunitinib—MAP4K4—spinal cord—bone cancer	0.000139	0.00297	CbGeAlD
Sunitinib—NUAK2—bone marrow—bone cancer	0.000138	0.00296	CbGeAlD
Sunitinib—TAOK3—connective tissue—bone cancer	0.000137	0.00294	CbGeAlD
Sunitinib—FLT3—bone marrow—bone cancer	0.000137	0.00294	CbGeAlD
Sunitinib—CSNK1A1—tendon—bone cancer	0.000137	0.00293	CbGeAlD
Sunitinib—MAP3K12—spinal cord—bone cancer	0.000137	0.00293	CbGeAlD
Sunitinib—PDGFRA—connective tissue—bone cancer	0.000137	0.00292	CbGeAlD
Sunitinib—CLK1—tendon—bone cancer	0.000136	0.00292	CbGeAlD
Sunitinib—RPS6KA3—bone marrow—bone cancer	0.000135	0.0029	CbGeAlD
Sunitinib—RPS6KA3—spinal cord—bone cancer	0.000135	0.00289	CbGeAlD
Sunitinib—MAP2K1—bone marrow—bone cancer	0.000135	0.00288	CbGeAlD
Sunitinib—MAP2K1—spinal cord—bone cancer	0.000134	0.00287	CbGeAlD
Sunitinib—CAMK2G—tendon—bone cancer	0.000134	0.00286	CbGeAlD
Sunitinib—BMP2K—tendon—bone cancer	0.000134	0.00286	CbGeAlD
Sunitinib—PRPF4—Idarubicin—Epirubicin—bone cancer	0.000133	0.067	CbGdCrCtD
Sunitinib—PRPF4—Daunorubicin—Epirubicin—bone cancer	0.000133	0.067	CbGdCrCtD
Sunitinib—CSNK1A1—bone marrow—bone cancer	0.000133	0.00284	CbGeAlD
Sunitinib—LRRK2—tendon—bone cancer	0.000133	0.00284	CbGeAlD
Sunitinib—CSNK1A1—spinal cord—bone cancer	0.000132	0.00283	CbGeAlD
Sunitinib—CLK1—bone marrow—bone cancer	0.000132	0.00282	CbGeAlD
Sunitinib—CLK1—spinal cord—bone cancer	0.000131	0.00281	CbGeAlD
Sunitinib—CAMK2G—bone marrow—bone cancer	0.00013	0.00277	CbGeAlD
Sunitinib—BMP2K—bone marrow—bone cancer	0.00013	0.00277	CbGeAlD
Sunitinib—PTK2B—tendon—bone cancer	0.000129	0.00276	CbGeAlD
Sunitinib—BMP2K—spinal cord—bone cancer	0.000129	0.00276	CbGeAlD
Sunitinib—CAMK2G—spinal cord—bone cancer	0.000129	0.00276	CbGeAlD
Sunitinib—LRRK2—bone marrow—bone cancer	0.000128	0.00275	CbGeAlD
Sunitinib—LRRK2—spinal cord—bone cancer	0.000128	0.00274	CbGeAlD
Sunitinib—CSNK1E—tendon—bone cancer	0.000127	0.00272	CbGeAlD
Sunitinib—FGFR1—tendon—bone cancer	0.000127	0.00272	CbGeAlD
Sunitinib—PRKAA1—bone marrow—bone cancer	0.000127	0.00271	CbGeAlD
Sunitinib—PTK2B—bone marrow—bone cancer	0.000125	0.00268	CbGeAlD
Sunitinib—IRAK4—tendon—bone cancer	0.000125	0.00268	CbGeAlD
Sunitinib—FLT4—bone marrow—bone cancer	0.000125	0.00267	CbGeAlD
Sunitinib—KDR—connective tissue—bone cancer	0.000123	0.00264	CbGeAlD
Sunitinib—PRPF4—Daunorubicin—Doxorubicin—bone cancer	0.000123	0.062	CbGdCrCtD
Sunitinib—PRPF4—Idarubicin—Doxorubicin—bone cancer	0.000123	0.062	CbGdCrCtD
Sunitinib—FGFR1—spinal cord—bone cancer	0.000123	0.00262	CbGeAlD
Sunitinib—CSNK1E—spinal cord—bone cancer	0.000123	0.00262	CbGeAlD
Sunitinib—MAP2K2—tendon—bone cancer	0.000122	0.00262	CbGeAlD
Sunitinib—ULK3—tendon—bone cancer	0.000122	0.00262	CbGeAlD
Sunitinib—IRAK4—bone marrow—bone cancer	0.000121	0.00259	CbGeAlD
Sunitinib—IRAK4—spinal cord—bone cancer	0.000121	0.00258	CbGeAlD
Sunitinib—MAP3K7—tendon—bone cancer	0.00012	0.00257	CbGeAlD
Sunitinib—CSF1R—connective tissue—bone cancer	0.00012	0.00257	CbGeAlD
Sunitinib—TBK1—tendon—bone cancer	0.000119	0.00254	CbGeAlD
Sunitinib—ULK3—bone marrow—bone cancer	0.000118	0.00254	CbGeAlD
Sunitinib—MAP2K2—bone marrow—bone cancer	0.000118	0.00254	CbGeAlD
Sunitinib—TYK2—tendon—bone cancer	0.000118	0.00253	CbGeAlD
Sunitinib—ULK3—spinal cord—bone cancer	0.000118	0.00252	CbGeAlD
Sunitinib—MAP2K2—spinal cord—bone cancer	0.000118	0.00252	CbGeAlD
Sunitinib—MAP3K2—bone marrow—bone cancer	0.000118	0.00252	CbGeAlD
Sunitinib—IRAK1—tendon—bone cancer	0.000117	0.00249	CbGeAlD
Sunitinib—MAP3K7—bone marrow—bone cancer	0.000117	0.00249	CbGeAlD
Sunitinib—MAP3K7—spinal cord—bone cancer	0.000116	0.00248	CbGeAlD
Sunitinib—TBK1—bone marrow—bone cancer	0.000115	0.00246	CbGeAlD
Sunitinib—TBK1—spinal cord—bone cancer	0.000115	0.00245	CbGeAlD
Sunitinib—TYK2—bone marrow—bone cancer	0.000114	0.00245	CbGeAlD
Sunitinib—RPS6KB1—tendon—bone cancer	0.000114	0.00245	CbGeAlD
Sunitinib—TYK2—spinal cord—bone cancer	0.000114	0.00244	CbGeAlD
Sunitinib—RET—tendon—bone cancer	0.000114	0.00243	CbGeAlD
Sunitinib—FGR—tendon—bone cancer	0.000114	0.00243	CbGeAlD
Sunitinib—AXL—tendon—bone cancer	0.000113	0.00242	CbGeAlD
Sunitinib—IRAK1—bone marrow—bone cancer	0.000113	0.00242	CbGeAlD
Sunitinib—RPS6KB1—bone marrow—bone cancer	0.000111	0.00237	CbGeAlD
Sunitinib—RPS6KB1—spinal cord—bone cancer	0.00011	0.00236	CbGeAlD
Sunitinib—FGR—bone marrow—bone cancer	0.00011	0.00236	CbGeAlD
Sunitinib—RET—spinal cord—bone cancer	0.00011	0.00235	CbGeAlD
Sunitinib—AXL—spinal cord—bone cancer	0.000109	0.00234	CbGeAlD
Sunitinib—KIT—connective tissue—bone cancer	0.000109	0.00234	CbGeAlD
Sunitinib—SLK—tendon—bone cancer	0.000109	0.00233	CbGeAlD
Sunitinib—JAK2—tendon—bone cancer	0.000107	0.0023	CbGeAlD
Sunitinib—PDGFRB—connective tissue—bone cancer	0.000107	0.00228	CbGeAlD
Sunitinib—FYN—tendon—bone cancer	0.000106	0.00227	CbGeAlD
Sunitinib—SLK—bone marrow—bone cancer	0.000106	0.00226	CbGeAlD
Sunitinib—PLK4—Idarubicin—Epirubicin—bone cancer	0.000105	0.053	CbGdCrCtD
Sunitinib—PLK4—Doxorubicin—Epirubicin—bone cancer	0.000105	0.053	CbGdCrCtD
Sunitinib—SLK—spinal cord—bone cancer	0.000105	0.00225	CbGeAlD
Sunitinib—FGFR2—spinal cord—bone cancer	0.000104	0.00223	CbGeAlD
Sunitinib—JAK2—bone marrow—bone cancer	0.000104	0.00223	CbGeAlD
Sunitinib—JAK2—spinal cord—bone cancer	0.000104	0.00222	CbGeAlD
Sunitinib—MAP4K5—tendon—bone cancer	0.000104	0.00222	CbGeAlD
Sunitinib—MAP3K3—tendon—bone cancer	0.000104	0.00222	CbGeAlD
Sunitinib—FYN—bone marrow—bone cancer	0.000103	0.0022	CbGeAlD
Sunitinib—FYN—spinal cord—bone cancer	0.000102	0.00219	CbGeAlD
Sunitinib—MAP4K5—bone marrow—bone cancer	0.0001	0.00215	CbGeAlD
Sunitinib—MAP3K3—bone marrow—bone cancer	0.0001	0.00215	CbGeAlD
Sunitinib—FLT1—tendon—bone cancer	0.0001	0.00214	CbGeAlD
Sunitinib—MAP4K5—spinal cord—bone cancer	9.99e-05	0.00214	CbGeAlD
Sunitinib—MAP3K3—spinal cord—bone cancer	9.99e-05	0.00214	CbGeAlD
Sunitinib—EPHB6—tendon—bone cancer	9.9e-05	0.00212	CbGeAlD
Sunitinib—PLK4—Epirubicin—Doxorubicin—bone cancer	9.74e-05	0.049	CbGdCrCtD
Sunitinib—PLK4—Idarubicin—Doxorubicin—bone cancer	9.74e-05	0.049	CbGdCrCtD
Sunitinib—FLT1—spinal cord—bone cancer	9.66e-05	0.00207	CbGeAlD
Sunitinib—YES1—tendon—bone cancer	9.57e-05	0.00205	CbGeAlD
Sunitinib—EPHB6—spinal cord—bone cancer	9.55e-05	0.00204	CbGeAlD
Sunitinib—STK10—tendon—bone cancer	9.48e-05	0.00203	CbGeAlD
Sunitinib—TAOK3—tendon—bone cancer	9.44e-05	0.00202	CbGeAlD
Sunitinib—PDGFRA—tendon—bone cancer	9.38e-05	0.00201	CbGeAlD
Sunitinib—CHEK2—Doxorubicin—Epirubicin—bone cancer	9.27e-05	0.0467	CbGdCrCtD
Sunitinib—YES1—bone marrow—bone cancer	9.27e-05	0.00198	CbGeAlD
Sunitinib—YES1—spinal cord—bone cancer	9.23e-05	0.00197	CbGeAlD
Sunitinib—STK10—bone marrow—bone cancer	9.18e-05	0.00196	CbGeAlD
Sunitinib—TAOK3—bone marrow—bone cancer	9.15e-05	0.00196	CbGeAlD
Sunitinib—TAOK3—spinal cord—bone cancer	9.11e-05	0.00195	CbGeAlD
Sunitinib—PDGFRA—spinal cord—bone cancer	9.05e-05	0.00194	CbGeAlD
Sunitinib—CHEK2—Epirubicin—Doxorubicin—bone cancer	8.58e-05	0.0432	CbGdCrCtD
Sunitinib—MAP2K5—tendon—bone cancer	8.46e-05	0.00181	CbGeAlD
Sunitinib—KDR—tendon—bone cancer	8.46e-05	0.00181	CbGeAlD
Sunitinib—CSF1R—tendon—bone cancer	8.26e-05	0.00177	CbGeAlD
Sunitinib—KDR—bone marrow—bone cancer	8.2e-05	0.00175	CbGeAlD
Sunitinib—KDR—spinal cord—bone cancer	8.16e-05	0.00175	CbGeAlD
Sunitinib—MAP2K5—spinal cord—bone cancer	8.16e-05	0.00175	CbGeAlD
Sunitinib—CSF1R—bone marrow—bone cancer	8e-05	0.00171	CbGeAlD
Sunitinib—CSF1R—spinal cord—bone cancer	7.97e-05	0.00171	CbGeAlD
Sunitinib—PDGFRB—tendon—bone cancer	7.33e-05	0.00157	CbGeAlD
Sunitinib—KIT—bone marrow—bone cancer	7.27e-05	0.00155	CbGeAlD
Sunitinib—KIT—spinal cord—bone cancer	7.23e-05	0.00155	CbGeAlD
Sunitinib—PDGFRB—bone marrow—bone cancer	7.1e-05	0.00152	CbGeAlD
Sunitinib—PDGFRB—spinal cord—bone cancer	7.07e-05	0.00151	CbGeAlD
Sunitinib—Dyspnoea—Cisplatin—bone cancer	6.49e-05	0.00098	CcSEcCtD
Sunitinib—Dry skin—Doxorubicin—bone cancer	6.45e-05	0.000975	CcSEcCtD
Sunitinib—Pancreatitis—Epirubicin—bone cancer	6.45e-05	0.000974	CcSEcCtD
Sunitinib—Abdominal pain upper—Doxorubicin—bone cancer	6.43e-05	0.000971	CcSEcCtD
Sunitinib—Hypokalaemia—Doxorubicin—bone cancer	6.41e-05	0.000968	CcSEcCtD
Sunitinib—Toxic epidermal necrolysis—Doxorubicin—bone cancer	6.34e-05	0.000957	CcSEcCtD
Sunitinib—Aspartate aminotransferase increased—Doxorubicin—bone cancer	6.34e-05	0.000957	CcSEcCtD
Sunitinib—Decreased appetite—Cisplatin—bone cancer	6.33e-05	0.000956	CcSEcCtD
Sunitinib—Bronchitis—Epirubicin—bone cancer	6.32e-05	0.000955	CcSEcCtD
Sunitinib—Pneumonia—Methotrexate—bone cancer	6.3e-05	0.000952	CcSEcCtD
Sunitinib—Nasopharyngitis—Doxorubicin—bone cancer	6.29e-05	0.000951	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Cisplatin—bone cancer	6.28e-05	0.000949	CcSEcCtD
Sunitinib—Infestation NOS—Methotrexate—bone cancer	6.26e-05	0.000946	CcSEcCtD
Sunitinib—Infestation—Methotrexate—bone cancer	6.26e-05	0.000946	CcSEcCtD
Sunitinib—Depression—Methotrexate—bone cancer	6.25e-05	0.000943	CcSEcCtD
Sunitinib—Pancytopenia—Epirubicin—bone cancer	6.24e-05	0.000943	CcSEcCtD
Sunitinib—Pain—Cisplatin—bone cancer	6.23e-05	0.00094	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Methotrexate—bone cancer	6.21e-05	0.000938	CcSEcCtD
Sunitinib—Muscular weakness—Doxorubicin—bone cancer	6.21e-05	0.000938	CcSEcCtD
Sunitinib—Alanine aminotransferase increased—Doxorubicin—bone cancer	6.21e-05	0.000938	CcSEcCtD
Sunitinib—Renal failure—Methotrexate—bone cancer	6.16e-05	0.00093	CcSEcCtD
Sunitinib—Neutropenia—Epirubicin—bone cancer	6.15e-05	0.000929	CcSEcCtD
Sunitinib—Abdominal distension—Doxorubicin—bone cancer	6.12e-05	0.000925	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Epirubicin—bone cancer	6.11e-05	0.000923	CcSEcCtD
Sunitinib—Stomatitis—Methotrexate—bone cancer	6.11e-05	0.000922	CcSEcCtD
Sunitinib—Dysphagia—Doxorubicin—bone cancer	6.08e-05	0.000919	CcSEcCtD
Sunitinib—Pancreatitis—Doxorubicin—bone cancer	5.96e-05	0.000901	CcSEcCtD
Sunitinib—Weight decreased—Epirubicin—bone cancer	5.95e-05	0.000898	CcSEcCtD
Sunitinib—Hyperglycaemia—Epirubicin—bone cancer	5.93e-05	0.000896	CcSEcCtD
Sunitinib—Hepatobiliary disease—Methotrexate—bone cancer	5.92e-05	0.000895	CcSEcCtD
Sunitinib—Epistaxis—Methotrexate—bone cancer	5.91e-05	0.000892	CcSEcCtD
Sunitinib—Pneumonia—Epirubicin—bone cancer	5.9e-05	0.000891	CcSEcCtD
Sunitinib—Infestation NOS—Epirubicin—bone cancer	5.86e-05	0.000885	CcSEcCtD
Sunitinib—Infestation—Epirubicin—bone cancer	5.86e-05	0.000885	CcSEcCtD
Sunitinib—Bronchitis—Doxorubicin—bone cancer	5.85e-05	0.000884	CcSEcCtD
Sunitinib—ABCC4—tendon—bone cancer	5.83e-05	0.00125	CbGeAlD
Sunitinib—Stevens-Johnson syndrome—Epirubicin—bone cancer	5.81e-05	0.000878	CcSEcCtD
Sunitinib—Pancytopenia—Doxorubicin—bone cancer	5.78e-05	0.000873	CcSEcCtD
Sunitinib—Renal failure—Epirubicin—bone cancer	5.76e-05	0.00087	CcSEcCtD
Sunitinib—Body temperature increased—Cisplatin—bone cancer	5.75e-05	0.000869	CcSEcCtD
Sunitinib—Neuropathy peripheral—Epirubicin—bone cancer	5.75e-05	0.000868	CcSEcCtD
Sunitinib—Stomatitis—Epirubicin—bone cancer	5.71e-05	0.000863	CcSEcCtD
Sunitinib—Urinary tract infection—Epirubicin—bone cancer	5.7e-05	0.000861	CcSEcCtD
Sunitinib—Neutropenia—Doxorubicin—bone cancer	5.69e-05	0.000859	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Doxorubicin—bone cancer	5.65e-05	0.000854	CcSEcCtD
Sunitinib—Haemoglobin—Methotrexate—bone cancer	5.65e-05	0.000854	CcSEcCtD
Sunitinib—ABCC4—bone marrow—bone cancer	5.65e-05	0.00121	CbGeAlD
Sunitinib—ABCC2—tendon—bone cancer	5.65e-05	0.00121	CbGeAlD
Sunitinib—Haemorrhage—Methotrexate—bone cancer	5.62e-05	0.000849	CcSEcCtD
Sunitinib—Hepatitis—Methotrexate—bone cancer	5.62e-05	0.000849	CcSEcCtD
Sunitinib—Urinary tract disorder—Methotrexate—bone cancer	5.55e-05	0.000839	CcSEcCtD
Sunitinib—Hepatobiliary disease—Epirubicin—bone cancer	5.54e-05	0.000837	CcSEcCtD
Sunitinib—Epistaxis—Epirubicin—bone cancer	5.53e-05	0.000835	CcSEcCtD
Sunitinib—Urethral disorder—Methotrexate—bone cancer	5.51e-05	0.000833	CcSEcCtD
Sunitinib—Weight decreased—Doxorubicin—bone cancer	5.5e-05	0.000831	CcSEcCtD
Sunitinib—Hyperglycaemia—Doxorubicin—bone cancer	5.49e-05	0.000829	CcSEcCtD
Sunitinib—Pneumonia—Doxorubicin—bone cancer	5.46e-05	0.000824	CcSEcCtD
Sunitinib—Infestation NOS—Doxorubicin—bone cancer	5.42e-05	0.000819	CcSEcCtD
Sunitinib—Infestation—Doxorubicin—bone cancer	5.42e-05	0.000819	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Doxorubicin—bone cancer	5.38e-05	0.000812	CcSEcCtD
Sunitinib—Hypersensitivity—Cisplatin—bone cancer	5.36e-05	0.00081	CcSEcCtD
Sunitinib—Bradycardia—Epirubicin—bone cancer	5.36e-05	0.000809	CcSEcCtD
Sunitinib—Renal failure—Doxorubicin—bone cancer	5.33e-05	0.000805	CcSEcCtD
Sunitinib—Erythema multiforme—Methotrexate—bone cancer	5.32e-05	0.000803	CcSEcCtD
Sunitinib—Neuropathy peripheral—Doxorubicin—bone cancer	5.32e-05	0.000803	CcSEcCtD
Sunitinib—Haemoglobin—Epirubicin—bone cancer	5.29e-05	0.000799	CcSEcCtD
Sunitinib—Stomatitis—Doxorubicin—bone cancer	5.29e-05	0.000799	CcSEcCtD
Sunitinib—Urinary tract infection—Doxorubicin—bone cancer	5.27e-05	0.000796	CcSEcCtD
Sunitinib—Haemorrhage—Epirubicin—bone cancer	5.26e-05	0.000795	CcSEcCtD
Sunitinib—Hepatitis—Epirubicin—bone cancer	5.26e-05	0.000795	CcSEcCtD
Sunitinib—Eye disorder—Methotrexate—bone cancer	5.25e-05	0.000794	CcSEcCtD
Sunitinib—Hypoaesthesia—Epirubicin—bone cancer	5.24e-05	0.000791	CcSEcCtD
Sunitinib—Asthenia—Cisplatin—bone cancer	5.22e-05	0.000789	CcSEcCtD
Sunitinib—Cardiac disorder—Methotrexate—bone cancer	5.22e-05	0.000788	CcSEcCtD
Sunitinib—Urinary tract disorder—Epirubicin—bone cancer	5.2e-05	0.000785	CcSEcCtD
Sunitinib—Oedema peripheral—Epirubicin—bone cancer	5.18e-05	0.000783	CcSEcCtD
Sunitinib—Connective tissue disorder—Epirubicin—bone cancer	5.17e-05	0.000781	CcSEcCtD
Sunitinib—Urethral disorder—Epirubicin—bone cancer	5.16e-05	0.000779	CcSEcCtD
Sunitinib—Hepatobiliary disease—Doxorubicin—bone cancer	5.13e-05	0.000775	CcSEcCtD
Sunitinib—Epistaxis—Doxorubicin—bone cancer	5.12e-05	0.000773	CcSEcCtD
Sunitinib—Angiopathy—Methotrexate—bone cancer	5.1e-05	0.000771	CcSEcCtD
Sunitinib—Immune system disorder—Methotrexate—bone cancer	5.08e-05	0.000767	CcSEcCtD
Sunitinib—Mediastinal disorder—Methotrexate—bone cancer	5.07e-05	0.000766	CcSEcCtD
Sunitinib—Chills—Methotrexate—bone cancer	5.05e-05	0.000762	CcSEcCtD
Sunitinib—Diarrhoea—Cisplatin—bone cancer	4.98e-05	0.000752	CcSEcCtD
Sunitinib—Erythema multiforme—Epirubicin—bone cancer	4.98e-05	0.000752	CcSEcCtD
Sunitinib—Alopecia—Methotrexate—bone cancer	4.97e-05	0.000751	CcSEcCtD
Sunitinib—Bradycardia—Doxorubicin—bone cancer	4.96e-05	0.000749	CcSEcCtD
Sunitinib—Mental disorder—Methotrexate—bone cancer	4.93e-05	0.000744	CcSEcCtD
Sunitinib—Eye disorder—Epirubicin—bone cancer	4.92e-05	0.000743	CcSEcCtD
Sunitinib—Erythema—Methotrexate—bone cancer	4.89e-05	0.000739	CcSEcCtD
Sunitinib—Malnutrition—Methotrexate—bone cancer	4.89e-05	0.000739	CcSEcCtD
Sunitinib—Haemoglobin—Doxorubicin—bone cancer	4.89e-05	0.000739	CcSEcCtD
Sunitinib—Cardiac disorder—Epirubicin—bone cancer	4.88e-05	0.000738	CcSEcCtD
Sunitinib—Flushing—Epirubicin—bone cancer	4.88e-05	0.000738	CcSEcCtD
Sunitinib—Haemorrhage—Doxorubicin—bone cancer	4.87e-05	0.000736	CcSEcCtD
Sunitinib—Hepatitis—Doxorubicin—bone cancer	4.87e-05	0.000736	CcSEcCtD
Sunitinib—Hypoaesthesia—Doxorubicin—bone cancer	4.84e-05	0.000732	CcSEcCtD
Sunitinib—Urinary tract disorder—Doxorubicin—bone cancer	4.81e-05	0.000726	CcSEcCtD
Sunitinib—Oedema peripheral—Doxorubicin—bone cancer	4.8e-05	0.000725	CcSEcCtD
Sunitinib—Dysgeusia—Methotrexate—bone cancer	4.79e-05	0.000724	CcSEcCtD
Sunitinib—Connective tissue disorder—Doxorubicin—bone cancer	4.78e-05	0.000723	CcSEcCtD
Sunitinib—Angiopathy—Epirubicin—bone cancer	4.77e-05	0.000721	CcSEcCtD
Sunitinib—Urethral disorder—Doxorubicin—bone cancer	4.77e-05	0.000721	CcSEcCtD
Sunitinib—Immune system disorder—Epirubicin—bone cancer	4.75e-05	0.000718	CcSEcCtD
Sunitinib—Mediastinal disorder—Epirubicin—bone cancer	4.74e-05	0.000716	CcSEcCtD
Sunitinib—Back pain—Methotrexate—bone cancer	4.73e-05	0.000715	CcSEcCtD
Sunitinib—Chills—Epirubicin—bone cancer	4.72e-05	0.000713	CcSEcCtD
Sunitinib—Arrhythmia—Epirubicin—bone cancer	4.7e-05	0.00071	CcSEcCtD
Sunitinib—Alopecia—Epirubicin—bone cancer	4.65e-05	0.000702	CcSEcCtD
Sunitinib—Vomiting—Cisplatin—bone cancer	4.63e-05	0.000699	CcSEcCtD
Sunitinib—Mental disorder—Epirubicin—bone cancer	4.61e-05	0.000696	CcSEcCtD
Sunitinib—Erythema multiforme—Doxorubicin—bone cancer	4.6e-05	0.000695	CcSEcCtD
Sunitinib—Rash—Cisplatin—bone cancer	4.59e-05	0.000693	CcSEcCtD
Sunitinib—Dermatitis—Cisplatin—bone cancer	4.59e-05	0.000693	CcSEcCtD
Sunitinib—Malnutrition—Epirubicin—bone cancer	4.58e-05	0.000692	CcSEcCtD
Sunitinib—Erythema—Epirubicin—bone cancer	4.58e-05	0.000692	CcSEcCtD
Sunitinib—Eye disorder—Doxorubicin—bone cancer	4.55e-05	0.000687	CcSEcCtD
Sunitinib—Anaemia—Methotrexate—bone cancer	4.52e-05	0.000683	CcSEcCtD
Sunitinib—Cardiac disorder—Doxorubicin—bone cancer	4.52e-05	0.000683	CcSEcCtD
Sunitinib—Flushing—Doxorubicin—bone cancer	4.52e-05	0.000683	CcSEcCtD
Sunitinib—Flatulence—Epirubicin—bone cancer	4.51e-05	0.000682	CcSEcCtD
Sunitinib—Dysgeusia—Epirubicin—bone cancer	4.49e-05	0.000678	CcSEcCtD
Sunitinib—KCNH2—bone marrow—bone cancer	4.48e-05	0.00096	CbGeAlD
Sunitinib—KCNH2—spinal cord—bone cancer	4.46e-05	0.000955	CbGeAlD
Sunitinib—Back pain—Epirubicin—bone cancer	4.43e-05	0.000669	CcSEcCtD
Sunitinib—Angiopathy—Doxorubicin—bone cancer	4.42e-05	0.000667	CcSEcCtD
Sunitinib—Muscle spasms—Epirubicin—bone cancer	4.4e-05	0.000665	CcSEcCtD
Sunitinib—Immune system disorder—Doxorubicin—bone cancer	4.4e-05	0.000664	CcSEcCtD
Sunitinib—Mediastinal disorder—Doxorubicin—bone cancer	4.39e-05	0.000663	CcSEcCtD
Sunitinib—Leukopenia—Methotrexate—bone cancer	4.38e-05	0.000662	CcSEcCtD
Sunitinib—Chills—Doxorubicin—bone cancer	4.37e-05	0.00066	CcSEcCtD
Sunitinib—Arrhythmia—Doxorubicin—bone cancer	4.35e-05	0.000657	CcSEcCtD
Sunitinib—Nausea—Cisplatin—bone cancer	4.32e-05	0.000653	CcSEcCtD
Sunitinib—Alopecia—Doxorubicin—bone cancer	4.3e-05	0.00065	CcSEcCtD
Sunitinib—Cough—Methotrexate—bone cancer	4.27e-05	0.000645	CcSEcCtD
Sunitinib—Mental disorder—Doxorubicin—bone cancer	4.27e-05	0.000644	CcSEcCtD
Sunitinib—Convulsion—Methotrexate—bone cancer	4.24e-05	0.000641	CcSEcCtD
Sunitinib—Erythema—Doxorubicin—bone cancer	4.24e-05	0.00064	CcSEcCtD
Sunitinib—Malnutrition—Doxorubicin—bone cancer	4.24e-05	0.00064	CcSEcCtD
Sunitinib—Anaemia—Epirubicin—bone cancer	4.23e-05	0.00064	CcSEcCtD
Sunitinib—Flatulence—Doxorubicin—bone cancer	4.18e-05	0.000631	CcSEcCtD
Sunitinib—Arthralgia—Methotrexate—bone cancer	4.17e-05	0.00063	CcSEcCtD
Sunitinib—Chest pain—Methotrexate—bone cancer	4.17e-05	0.00063	CcSEcCtD
Sunitinib—Myalgia—Methotrexate—bone cancer	4.17e-05	0.00063	CcSEcCtD
Sunitinib—Dysgeusia—Doxorubicin—bone cancer	4.15e-05	0.000627	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	4.14e-05	0.000625	CcSEcCtD
Sunitinib—Leukopenia—Epirubicin—bone cancer	4.1e-05	0.000619	CcSEcCtD
Sunitinib—Back pain—Doxorubicin—bone cancer	4.1e-05	0.000619	CcSEcCtD
Sunitinib—Muscle spasms—Doxorubicin—bone cancer	4.07e-05	0.000616	CcSEcCtD
Sunitinib—Cough—Epirubicin—bone cancer	4e-05	0.000604	CcSEcCtD
Sunitinib—ABCG2—bone marrow—bone cancer	3.99e-05	0.000854	CbGeAlD
Sunitinib—ABCG2—spinal cord—bone cancer	3.97e-05	0.00085	CbGeAlD
Sunitinib—Convulsion—Epirubicin—bone cancer	3.97e-05	0.0006	CcSEcCtD
Sunitinib—Infection—Methotrexate—bone cancer	3.97e-05	0.0006	CcSEcCtD
Sunitinib—Hypertension—Epirubicin—bone cancer	3.95e-05	0.000597	CcSEcCtD
Sunitinib—Nervous system disorder—Methotrexate—bone cancer	3.92e-05	0.000592	CcSEcCtD
Sunitinib—Anaemia—Doxorubicin—bone cancer	3.92e-05	0.000592	CcSEcCtD
Sunitinib—Thrombocytopenia—Methotrexate—bone cancer	3.91e-05	0.000591	CcSEcCtD
Sunitinib—Chest pain—Epirubicin—bone cancer	3.9e-05	0.000589	CcSEcCtD
Sunitinib—Arthralgia—Epirubicin—bone cancer	3.9e-05	0.000589	CcSEcCtD
Sunitinib—Myalgia—Epirubicin—bone cancer	3.9e-05	0.000589	CcSEcCtD
Sunitinib—Skin disorder—Methotrexate—bone cancer	3.88e-05	0.000586	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	3.87e-05	0.000585	CcSEcCtD
Sunitinib—Dry mouth—Epirubicin—bone cancer	3.81e-05	0.000576	CcSEcCtD
Sunitinib—Anorexia—Methotrexate—bone cancer	3.81e-05	0.000575	CcSEcCtD
Sunitinib—Leukopenia—Doxorubicin—bone cancer	3.79e-05	0.000573	CcSEcCtD
Sunitinib—Oedema—Epirubicin—bone cancer	3.74e-05	0.000565	CcSEcCtD
Sunitinib—Infection—Epirubicin—bone cancer	3.71e-05	0.000561	CcSEcCtD
Sunitinib—Cough—Doxorubicin—bone cancer	3.7e-05	0.000559	CcSEcCtD
Sunitinib—Shock—Epirubicin—bone cancer	3.68e-05	0.000556	CcSEcCtD
Sunitinib—Convulsion—Doxorubicin—bone cancer	3.67e-05	0.000555	CcSEcCtD
Sunitinib—Nervous system disorder—Epirubicin—bone cancer	3.67e-05	0.000554	CcSEcCtD
Sunitinib—Thrombocytopenia—Epirubicin—bone cancer	3.66e-05	0.000553	CcSEcCtD
Sunitinib—Hypertension—Doxorubicin—bone cancer	3.66e-05	0.000553	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Methotrexate—bone cancer	3.64e-05	0.00055	CcSEcCtD
Sunitinib—Skin disorder—Epirubicin—bone cancer	3.63e-05	0.000549	CcSEcCtD
Sunitinib—Insomnia—Methotrexate—bone cancer	3.61e-05	0.000546	CcSEcCtD
Sunitinib—Myalgia—Doxorubicin—bone cancer	3.61e-05	0.000545	CcSEcCtD
Sunitinib—Arthralgia—Doxorubicin—bone cancer	3.61e-05	0.000545	CcSEcCtD
Sunitinib—Chest pain—Doxorubicin—bone cancer	3.61e-05	0.000545	CcSEcCtD
Sunitinib—Paraesthesia—Methotrexate—bone cancer	3.59e-05	0.000542	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	3.58e-05	0.000541	CcSEcCtD
Sunitinib—Anorexia—Epirubicin—bone cancer	3.56e-05	0.000538	CcSEcCtD
Sunitinib—Dyspnoea—Methotrexate—bone cancer	3.56e-05	0.000538	CcSEcCtD
Sunitinib—Dry mouth—Doxorubicin—bone cancer	3.53e-05	0.000533	CcSEcCtD
Sunitinib—Dyspepsia—Methotrexate—bone cancer	3.52e-05	0.000531	CcSEcCtD
Sunitinib—Decreased appetite—Methotrexate—bone cancer	3.47e-05	0.000525	CcSEcCtD
Sunitinib—Oedema—Doxorubicin—bone cancer	3.46e-05	0.000523	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Methotrexate—bone cancer	3.45e-05	0.000521	CcSEcCtD
Sunitinib—Fatigue—Methotrexate—bone cancer	3.44e-05	0.00052	CcSEcCtD
Sunitinib—Infection—Doxorubicin—bone cancer	3.44e-05	0.000519	CcSEcCtD
Sunitinib—Pain—Methotrexate—bone cancer	3.42e-05	0.000516	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Epirubicin—bone cancer	3.41e-05	0.000515	CcSEcCtD
Sunitinib—Shock—Doxorubicin—bone cancer	3.4e-05	0.000514	CcSEcCtD
Sunitinib—Nervous system disorder—Doxorubicin—bone cancer	3.39e-05	0.000512	CcSEcCtD
Sunitinib—Thrombocytopenia—Doxorubicin—bone cancer	3.39e-05	0.000512	CcSEcCtD
Sunitinib—Insomnia—Epirubicin—bone cancer	3.38e-05	0.000511	CcSEcCtD
Sunitinib—Skin disorder—Doxorubicin—bone cancer	3.36e-05	0.000508	CcSEcCtD
Sunitinib—Paraesthesia—Epirubicin—bone cancer	3.36e-05	0.000507	CcSEcCtD
Sunitinib—Dyspnoea—Epirubicin—bone cancer	3.33e-05	0.000503	CcSEcCtD
Sunitinib—Anorexia—Doxorubicin—bone cancer	3.3e-05	0.000498	CcSEcCtD
Sunitinib—Dyspepsia—Epirubicin—bone cancer	3.29e-05	0.000497	CcSEcCtD
Sunitinib—Gastrointestinal pain—Methotrexate—bone cancer	3.27e-05	0.000493	CcSEcCtD
Sunitinib—Decreased appetite—Epirubicin—bone cancer	3.25e-05	0.000491	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Epirubicin—bone cancer	3.23e-05	0.000488	CcSEcCtD
Sunitinib—Fatigue—Epirubicin—bone cancer	3.22e-05	0.000487	CcSEcCtD
Sunitinib—Pain—Epirubicin—bone cancer	3.2e-05	0.000483	CcSEcCtD
Sunitinib—Constipation—Epirubicin—bone cancer	3.2e-05	0.000483	CcSEcCtD
Sunitinib—Abdominal pain—Methotrexate—bone cancer	3.16e-05	0.000477	CcSEcCtD
Sunitinib—Body temperature increased—Methotrexate—bone cancer	3.16e-05	0.000477	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Doxorubicin—bone cancer	3.15e-05	0.000476	CcSEcCtD
Sunitinib—Insomnia—Doxorubicin—bone cancer	3.13e-05	0.000473	CcSEcCtD
Sunitinib—Paraesthesia—Doxorubicin—bone cancer	3.11e-05	0.000469	CcSEcCtD
Sunitinib—Dyspnoea—Doxorubicin—bone cancer	3.08e-05	0.000466	CcSEcCtD
Sunitinib—Gastrointestinal pain—Epirubicin—bone cancer	3.06e-05	0.000462	CcSEcCtD
Sunitinib—Dyspepsia—Doxorubicin—bone cancer	3.04e-05	0.00046	CcSEcCtD
Sunitinib—Decreased appetite—Doxorubicin—bone cancer	3.01e-05	0.000454	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Doxorubicin—bone cancer	2.99e-05	0.000451	CcSEcCtD
Sunitinib—Fatigue—Doxorubicin—bone cancer	2.98e-05	0.000451	CcSEcCtD
Sunitinib—Pain—Doxorubicin—bone cancer	2.96e-05	0.000447	CcSEcCtD
Sunitinib—Constipation—Doxorubicin—bone cancer	2.96e-05	0.000447	CcSEcCtD
Sunitinib—Abdominal pain—Epirubicin—bone cancer	2.96e-05	0.000446	CcSEcCtD
Sunitinib—Body temperature increased—Epirubicin—bone cancer	2.96e-05	0.000446	CcSEcCtD
Sunitinib—Hypersensitivity—Methotrexate—bone cancer	2.94e-05	0.000445	CcSEcCtD
Sunitinib—Asthenia—Methotrexate—bone cancer	2.87e-05	0.000433	CcSEcCtD
Sunitinib—Gastrointestinal pain—Doxorubicin—bone cancer	2.83e-05	0.000427	CcSEcCtD
Sunitinib—Pruritus—Methotrexate—bone cancer	2.83e-05	0.000427	CcSEcCtD
Sunitinib—Hypersensitivity—Epirubicin—bone cancer	2.75e-05	0.000416	CcSEcCtD
Sunitinib—Abdominal pain—Doxorubicin—bone cancer	2.73e-05	0.000413	CcSEcCtD
Sunitinib—Body temperature increased—Doxorubicin—bone cancer	2.73e-05	0.000413	CcSEcCtD
Sunitinib—Diarrhoea—Methotrexate—bone cancer	2.73e-05	0.000413	CcSEcCtD
Sunitinib—Asthenia—Epirubicin—bone cancer	2.68e-05	0.000405	CcSEcCtD
Sunitinib—Pruritus—Epirubicin—bone cancer	2.64e-05	0.0004	CcSEcCtD
Sunitinib—Dizziness—Methotrexate—bone cancer	2.64e-05	0.000399	CcSEcCtD
Sunitinib—Diarrhoea—Epirubicin—bone cancer	2.56e-05	0.000386	CcSEcCtD
Sunitinib—Hypersensitivity—Doxorubicin—bone cancer	2.55e-05	0.000385	CcSEcCtD
Sunitinib—Vomiting—Methotrexate—bone cancer	2.54e-05	0.000384	CcSEcCtD
Sunitinib—Rash—Methotrexate—bone cancer	2.52e-05	0.00038	CcSEcCtD
Sunitinib—Dermatitis—Methotrexate—bone cancer	2.52e-05	0.00038	CcSEcCtD
Sunitinib—Headache—Methotrexate—bone cancer	2.5e-05	0.000378	CcSEcCtD
Sunitinib—Asthenia—Doxorubicin—bone cancer	2.48e-05	0.000375	CcSEcCtD
Sunitinib—Dizziness—Epirubicin—bone cancer	2.47e-05	0.000373	CcSEcCtD
Sunitinib—Pruritus—Doxorubicin—bone cancer	2.45e-05	0.00037	CcSEcCtD
Sunitinib—Vomiting—Epirubicin—bone cancer	2.38e-05	0.000359	CcSEcCtD
Sunitinib—Nausea—Methotrexate—bone cancer	2.37e-05	0.000358	CcSEcCtD
Sunitinib—Diarrhoea—Doxorubicin—bone cancer	2.37e-05	0.000358	CcSEcCtD
Sunitinib—Rash—Epirubicin—bone cancer	2.36e-05	0.000356	CcSEcCtD
Sunitinib—Dermatitis—Epirubicin—bone cancer	2.35e-05	0.000356	CcSEcCtD
Sunitinib—Headache—Epirubicin—bone cancer	2.34e-05	0.000354	CcSEcCtD
Sunitinib—Dizziness—Doxorubicin—bone cancer	2.29e-05	0.000346	CcSEcCtD
Sunitinib—Nausea—Epirubicin—bone cancer	2.22e-05	0.000335	CcSEcCtD
Sunitinib—Vomiting—Doxorubicin—bone cancer	2.2e-05	0.000332	CcSEcCtD
Sunitinib—Rash—Doxorubicin—bone cancer	2.18e-05	0.000329	CcSEcCtD
Sunitinib—Dermatitis—Doxorubicin—bone cancer	2.18e-05	0.000329	CcSEcCtD
Sunitinib—Headache—Doxorubicin—bone cancer	2.17e-05	0.000327	CcSEcCtD
Sunitinib—Nausea—Doxorubicin—bone cancer	2.05e-05	0.00031	CcSEcCtD
Sunitinib—ABCB1—bone marrow—bone cancer	1.97e-05	0.000421	CbGeAlD
Sunitinib—ABCB1—spinal cord—bone cancer	1.96e-05	0.000419	CbGeAlD
Sunitinib—FYN—Disease—KIT—bone cancer	1.68e-06	1.73e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—BRAF—bone cancer	1.68e-06	1.73e-05	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—EGFR—bone cancer	1.67e-06	1.72e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Adaptive Immune System—EGFR—bone cancer	1.67e-06	1.72e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Innate Immune System—EGFR—bone cancer	1.67e-06	1.72e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—KIT—bone cancer	1.67e-06	1.72e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—GSTP1—bone cancer	1.66e-06	1.71e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—MDM2—bone cancer	1.66e-06	1.71e-05	CbGpPWpGaD
Sunitinib—BLK—Immune System—EGFR—bone cancer	1.66e-06	1.71e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—MDM2—bone cancer	1.65e-06	1.7e-05	CbGpPWpGaD
Sunitinib—FGR—Immune System—EGFR—bone cancer	1.65e-06	1.7e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—MDM2—bone cancer	1.65e-06	1.7e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—GSTP1—bone cancer	1.65e-06	1.7e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—DHFR—bone cancer	1.64e-06	1.69e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—JUN—bone cancer	1.64e-06	1.69e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—MDM2—bone cancer	1.64e-06	1.69e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TGFBR2—bone cancer	1.64e-06	1.69e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—BRAF—bone cancer	1.64e-06	1.69e-05	CbGpPWpGaD
Sunitinib—PAK3—Signaling Pathways—TP53—bone cancer	1.63e-06	1.68e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—IGF1R—bone cancer	1.62e-06	1.67e-05	CbGpPWpGaD
Sunitinib—FYN—Adaptive Immune System—EGFR—bone cancer	1.61e-06	1.66e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—IGF1R—bone cancer	1.61e-06	1.66e-05	CbGpPWpGaD
Sunitinib—KIT—Disease—MDM2—bone cancer	1.61e-06	1.66e-05	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—JUN—bone cancer	1.61e-06	1.66e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—MDM2—bone cancer	1.6e-06	1.66e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—KIT—bone cancer	1.6e-06	1.65e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—PTGS2—bone cancer	1.6e-06	1.65e-05	CbGpPWpGaD
Sunitinib—JAK2—Innate Immune System—EGFR—bone cancer	1.6e-06	1.65e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—KIT—bone cancer	1.59e-06	1.64e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—EGFR—bone cancer	1.59e-06	1.64e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—MMP9—bone cancer	1.59e-06	1.64e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—PTGS2—bone cancer	1.58e-06	1.63e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—BRAF—bone cancer	1.58e-06	1.63e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—BRAF—bone cancer	1.57e-06	1.62e-05	CbGpPWpGaD
Sunitinib—FYN—Hemostasis—TP53—bone cancer	1.57e-06	1.61e-05	CbGpPWpGaD
Sunitinib—TYK2—Immune System—JUN—bone cancer	1.56e-06	1.61e-05	CbGpPWpGaD
Sunitinib—KIT—Disease—PTGS2—bone cancer	1.55e-06	1.6e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—MDM2—bone cancer	1.55e-06	1.59e-05	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—JUN—bone cancer	1.54e-06	1.59e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IGF1R—bone cancer	1.54e-06	1.59e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—JUN—bone cancer	1.54e-06	1.58e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—MDM2—bone cancer	1.54e-06	1.58e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—GNA11—bone cancer	1.53e-06	1.58e-05	CbGpPWpGaD
Sunitinib—FGFR1—Disease—MDM2—bone cancer	1.52e-06	1.57e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—JUN—bone cancer	1.52e-06	1.57e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—MDM2—bone cancer	1.52e-06	1.57e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—MDM2—bone cancer	1.52e-06	1.57e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—KIT—bone cancer	1.52e-06	1.57e-05	CbGpPWpGaD
Sunitinib—KIT—Immune System—JUN—bone cancer	1.51e-06	1.56e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—JUN—bone cancer	1.51e-06	1.56e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—BRAF—bone cancer	1.5e-06	1.55e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—EGFR—bone cancer	1.5e-06	1.55e-05	CbGpPWpGaD
Sunitinib—PRKAA2—Signaling Pathways—TP53—bone cancer	1.5e-06	1.55e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—BRAF—bone cancer	1.5e-06	1.55e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—MMP9—bone cancer	1.49e-06	1.54e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—EGFR—bone cancer	1.49e-06	1.54e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—MDM2—bone cancer	1.49e-06	1.54e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—MDM2—bone cancer	1.49e-06	1.54e-05	CbGpPWpGaD
Sunitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.49e-06	1.54e-05	CbGpPWpGaD
Sunitinib—JAK2—Hemostasis—TP53—bone cancer	1.49e-06	1.53e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—MDM2—bone cancer	1.48e-06	1.53e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—MMP9—bone cancer	1.48e-06	1.53e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—KIT—bone cancer	1.47e-06	1.52e-05	CbGpPWpGaD
Sunitinib—FGFR1—Disease—PTGS2—bone cancer	1.47e-06	1.52e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—PTGS2—bone cancer	1.47e-06	1.51e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—KIT—bone cancer	1.45e-06	1.5e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—MDM2—bone cancer	1.45e-06	1.5e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—JUN—bone cancer	1.44e-06	1.48e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—JUN—bone cancer	1.43e-06	1.48e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—MDM2—bone cancer	1.43e-06	1.48e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—KIT—bone cancer	1.43e-06	1.47e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—BRAF—bone cancer	1.43e-06	1.47e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—MDM2—bone cancer	1.42e-06	1.47e-05	CbGpPWpGaD
Sunitinib—RPS6KA5—Signaling Pathways—TP53—bone cancer	1.42e-06	1.46e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—MDM2—bone cancer	1.4e-06	1.45e-05	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—TP53—bone cancer	1.4e-06	1.45e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—JUN—bone cancer	1.39e-06	1.44e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—CYP3A4—bone cancer	1.39e-06	1.43e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—BRAF—bone cancer	1.38e-06	1.43e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—MDM2—bone cancer	1.37e-06	1.41e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—BRAF—bone cancer	1.37e-06	1.41e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—MDM2—bone cancer	1.36e-06	1.4e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—MMP9—bone cancer	1.36e-06	1.4e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—KIT—bone cancer	1.36e-06	1.4e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—PTGS2—bone cancer	1.35e-06	1.4e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—KIT—bone cancer	1.35e-06	1.4e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—JUN—bone cancer	1.34e-06	1.39e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—BRAF—bone cancer	1.34e-06	1.39e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—BRAF—bone cancer	1.34e-06	1.39e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling by GPCR—EGFR—bone cancer	1.34e-06	1.38e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—TP53—bone cancer	1.34e-06	1.38e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—ENO2—bone cancer	1.33e-06	1.38e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—JUN—bone cancer	1.33e-06	1.38e-05	CbGpPWpGaD
Sunitinib—YES1—Immune System—EGFR—bone cancer	1.33e-06	1.37e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—JUN—bone cancer	1.32e-06	1.36e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—PTGS2—bone cancer	1.32e-06	1.36e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—MDM2—bone cancer	1.32e-06	1.36e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—MDM2—bone cancer	1.31e-06	1.36e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—MMP9—bone cancer	1.31e-06	1.35e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—MMP9—bone cancer	1.3e-06	1.34e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—JUN—bone cancer	1.29e-06	1.34e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—JUN—bone cancer	1.29e-06	1.34e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—JUN—bone cancer	1.29e-06	1.33e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—EGFR—bone cancer	1.29e-06	1.33e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—BRAF—bone cancer	1.27e-06	1.31e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—PTGS2—bone cancer	1.27e-06	1.31e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—BRAF—bone cancer	1.27e-06	1.31e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—PTGS2—bone cancer	1.27e-06	1.31e-05	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—EGFR—bone cancer	1.26e-06	1.3e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—JUN—bone cancer	1.26e-06	1.3e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—TP53—bone cancer	1.26e-06	1.3e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—MDM2—bone cancer	1.26e-06	1.3e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—MMP9—bone cancer	1.26e-06	1.3e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—MMP9—bone cancer	1.26e-06	1.3e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—MDM2—bone cancer	1.26e-06	1.3e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—TP53—bone cancer	1.25e-06	1.29e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—KIT—bone cancer	1.25e-06	1.29e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—JUN—bone cancer	1.24e-06	1.28e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—DHFR—bone cancer	1.24e-06	1.28e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—JUN—bone cancer	1.24e-06	1.28e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—MMP9—bone cancer	1.23e-06	1.27e-05	CbGpPWpGaD
Sunitinib—TYK2—Immune System—EGFR—bone cancer	1.23e-06	1.26e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—KIT—bone cancer	1.22e-06	1.26e-05	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—EGFR—bone cancer	1.21e-06	1.25e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—PTGS2—bone cancer	1.21e-06	1.25e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—EGFR—bone cancer	1.21e-06	1.25e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—EGFR—bone cancer	1.2e-06	1.23e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—MDM2—bone cancer	1.19e-06	1.23e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—GSTP1—bone cancer	1.19e-06	1.23e-05	CbGpPWpGaD
Sunitinib—KIT—Immune System—EGFR—bone cancer	1.19e-06	1.23e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—EGFR—bone cancer	1.19e-06	1.23e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—JUN—bone cancer	1.18e-06	1.22e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—KIT—bone cancer	1.17e-06	1.21e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—BRAF—bone cancer	1.17e-06	1.21e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—KIT—bone cancer	1.17e-06	1.2e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MDM2—bone cancer	1.16e-06	1.2e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—GNA11—bone cancer	1.16e-06	1.19e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MDM2—bone cancer	1.15e-06	1.18e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—BRAF—bone cancer	1.15e-06	1.18e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—EGFR—bone cancer	1.14e-06	1.17e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—EGFR—bone cancer	1.13e-06	1.17e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—EGFR—bone cancer	1.13e-06	1.16e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—EGFR—bone cancer	1.13e-06	1.16e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MDM2—bone cancer	1.13e-06	1.16e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MDM2—bone cancer	1.13e-06	1.16e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—EGFR—bone cancer	1.12e-06	1.15e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—KIT—bone cancer	1.12e-06	1.15e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—BRAF—bone cancer	1.1e-06	1.14e-05	CbGpPWpGaD
Sunitinib—KIT—Disease—EGFR—bone cancer	1.1e-06	1.13e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—BRAF—bone cancer	1.1e-06	1.13e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—EGFR—bone cancer	1.1e-06	1.13e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—JUN—bone cancer	1.1e-06	1.13e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—TP53—bone cancer	1.08e-06	1.11e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MDM2—bone cancer	1.07e-06	1.1e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—MMP9—bone cancer	1.07e-06	1.1e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MDM2—bone cancer	1.06e-06	1.1e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—EGFR—bone cancer	1.06e-06	1.1e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—EGFR—bone cancer	1.06e-06	1.09e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CYP3A4—bone cancer	1.05e-06	1.08e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—EGFR—bone cancer	1.05e-06	1.08e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—BRAF—bone cancer	1.05e-06	1.08e-05	CbGpPWpGaD
Sunitinib—FGFR1—Disease—EGFR—bone cancer	1.04e-06	1.07e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—EGFR—bone cancer	1.04e-06	1.07e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—EGFR—bone cancer	1.04e-06	1.07e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—JUN—bone cancer	1.04e-06	1.07e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—EGFR—bone cancer	1.02e-06	1.05e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—EGFR—bone cancer	1.02e-06	1.05e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—EGFR—bone cancer	1.02e-06	1.05e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—EGFR—bone cancer	1.01e-06	1.05e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—TP53—bone cancer	1.01e-06	1.05e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—MMP9—bone cancer	1.01e-06	1.04e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—JUN—bone cancer	1.01e-06	1.04e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—TP53—bone cancer	1e-06	1.04e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—JUN—bone cancer	9.96e-07	1.03e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—EGFR—bone cancer	9.92e-07	1.02e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MDM2—bone cancer	9.83e-07	1.01e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MMP9—bone cancer	9.81e-07	1.01e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—JUN—bone cancer	9.78e-07	1.01e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—JUN—bone cancer	9.78e-07	1.01e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—EGFR—bone cancer	9.77e-07	1.01e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—EGFR—bone cancer	9.72e-07	1e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MMP9—bone cancer	9.69e-07	9.99e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—EGFR—bone cancer	9.59e-07	9.9e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MDM2—bone cancer	9.59e-07	9.9e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MMP9—bone cancer	9.51e-07	9.82e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MMP9—bone cancer	9.51e-07	9.82e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—EGFR—bone cancer	9.36e-07	9.66e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—EGFR—bone cancer	9.29e-07	9.59e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—JUN—bone cancer	9.28e-07	9.57e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—JUN—bone cancer	9.26e-07	9.55e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MDM2—bone cancer	9.25e-07	9.54e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—TP53—bone cancer	9.21e-07	9.5e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MDM2—bone cancer	9.2e-07	9.49e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MMP9—bone cancer	9.03e-07	9.32e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—EGFR—bone cancer	9.02e-07	9.31e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MMP9—bone cancer	9.01e-07	9.29e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—EGFR—bone cancer	8.98e-07	9.26e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—GSTP1—bone cancer	8.97e-07	9.26e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—TP53—bone cancer	8.87e-07	9.15e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—TP53—bone cancer	8.81e-07	9.09e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MDM2—bone cancer	8.79e-07	9.07e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—EGFR—bone cancer	8.61e-07	8.88e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PTGS2—bone cancer	8.6e-07	8.87e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—EGFR—bone cancer	8.58e-07	8.85e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—JUN—bone cancer	8.55e-07	8.82e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—TP53—bone cancer	8.54e-07	8.81e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—TP53—bone cancer	8.54e-07	8.81e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PTGS2—bone cancer	8.52e-07	8.79e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—JUN—bone cancer	8.34e-07	8.6e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—TP53—bone cancer	8.33e-07	8.59e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MMP9—bone cancer	8.31e-07	8.58e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ENO2—bone cancer	8.22e-07	8.49e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—EGFR—bone cancer	8.17e-07	8.42e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MMP9—bone cancer	8.11e-07	8.37e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—JUN—bone cancer	8.04e-07	8.29e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—JUN—bone cancer	8e-07	8.25e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—EGFR—bone cancer	7.93e-07	8.18e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—EGFR—bone cancer	7.83e-07	8.08e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MMP9—bone cancer	7.82e-07	8.07e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MMP9—bone cancer	7.78e-07	8.03e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—EGFR—bone cancer	7.69e-07	7.93e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—EGFR—bone cancer	7.69e-07	7.93e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—JUN—bone cancer	7.64e-07	7.88e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—DHFR—bone cancer	7.63e-07	7.87e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MMP9—bone cancer	7.43e-07	7.67e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—EGFR—bone cancer	7.3e-07	7.53e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—EGFR—bone cancer	7.28e-07	7.51e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—bone cancer	7.23e-07	7.46e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GNA11—bone cancer	7.13e-07	7.36e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—bone cancer	6.86e-07	7.07e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—EGFR—bone cancer	6.72e-07	6.93e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—bone cancer	6.66e-07	6.87e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—bone cancer	6.57e-07	6.78e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—EGFR—bone cancer	6.56e-07	6.76e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—bone cancer	6.46e-07	6.66e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—bone cancer	6.46e-07	6.66e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—EGFR—bone cancer	6.32e-07	6.52e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—EGFR—bone cancer	6.29e-07	6.49e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTGS2—bone cancer	6.16e-07	6.36e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—bone cancer	6.13e-07	6.32e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—bone cancer	6.11e-07	6.3e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—EGFR—bone cancer	6.01e-07	6.2e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—bone cancer	5.64e-07	5.82e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GSTP1—bone cancer	5.53e-07	5.7e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—bone cancer	5.5e-07	5.68e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—bone cancer	5.31e-07	5.47e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—bone cancer	5.28e-07	5.45e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—bone cancer	5.04e-07	5.2e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTGS2—bone cancer	4.65e-07	4.8e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTGS2—bone cancer	2.86e-07	2.96e-06	CbGpPWpGaD
